EMBioSys is developing a platform technology of therapeutic non-pharmacological, electrode-free wearable garments that deliver iEF Therapy (low level induced electric fields) to improve patient outcomes for treatment of breast cancer. The market entry product will target triple-negative breast cancer (TNBC), which accounts for 40% of all breast cancer mortality.
iEF Therapy inhibits cancer metastasis, shrinks the primary tumor, improves efficacy of standard of care chemotherapy, and boosts the natural immune response while selectively targeting only cancer cells.
This novel technology offers physicians a low risk, easily tolerated therapy to potentiate the standard of care for treatment of solid tumors, starting with breast cancer.
Company Details
- Employees
- 4
- Founded
- -
- Industry
- Medical Equipment Manufacturing
- NAICS
-
Medical Equipment and Supplies ManufacturingSurgical and Medical Instrument ManufacturingSurgical Appliance and Supplies ManufacturingDental Equipment and Supplies ManufacturingOphthalmic Goods ManufacturingDental Laboratories
- Website
- https://www.embiosys.com/
- Keywords
- Providence.
Embiosys Questions
Embiosys's website is https://www.embiosys.com/
Embiosys's LinkedIn profile is https://www.linkedin.com/company/embiosys
Embiosys has
4 employees.
View email and phone details for 4
employees at Embiosys.
Embiosys's industry is
Medical Equipment Manufacturing
Embiosys's top competitors are
Native Orthopaedics,
Docs For Health,
Reach Neuro, Inc.,
Novocure,
New Phase,
Lectra Tech,
Qv Bioelectronics,
Cartwheel,
Ablatus - Creators Of Luna,
Mirai Medical.
Embiosys's categories are Medical Equipment Manufacturing
Embiosys's founding year is 2022
